At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 520 enrolled
Drug / intervention
Ciclesonidedrug
Likely dose
Ciclesonide 160 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Control of Moderate or Severe Asthma With 160, 320 and 640 mcg Ciclesonide/Day. A One-year Randomised, Double-blind, Multicenter Trial.
In Brief
A Phase 3 clinical trial evaluating Ciclesonide for Bronchial Asthma. Completed, enrolled 520 participants across 30 sites in 5 countries.
Detailed Summary
The aim of the trial is to investigate asthma control with 160 to 640 mcg ciclesonide/day. Asthma control will be assessed by the Asthma Control Questionnaire (ACQ).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBronchial Asthma
CountriesArgentina, Brazil, Germany, Israel, Russia
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 2011
Enrollment StartNov 2011
Primary CompletionAug 2014
TodayJul 2026
First PostedOct 19, 2011
Enrollment StartNov 1, 2011
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 14.7 years ago
Interventions
Ciclesonidedrug
During the treatment period subjects will inhale two puffs of either 40, 80 or 160 μg ciclesonide in the morning and the evening (corresponding to a total daily dose of 160, 320 or 640 μg)